Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer

[1]  P. Sieger,et al.  pH‐dependent solubility and permeability profiles: A useful tool for prediction of oral bioavailability , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  G. Robertson,et al.  Effect of lysosomotropic molecules on cellular homeostasis , 2017, Pharmacological research.

[3]  Manuel Hidalgo,et al.  Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Katoh.  Therapeutics Targeting FGF Signaling Network in Human Diseases. , 2016, Trends in pharmacological sciences.

[5]  R. Kaiser,et al.  Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer , 2016, Journal of clinical pharmacology.

[6]  D. Richardson,et al.  Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance. , 2016, Free radical biology & medicine.

[7]  D. Lötsch,et al.  Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression , 2016, Oncotarget.

[8]  J. Schellens,et al.  Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[9]  M. Katoh.  FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review) , 2016, International journal of molecular medicine.

[10]  K. O'Byrne,et al.  Targeting the fibroblast growth factor receptor family in cancer. , 2016, Cancer treatment reviews.

[11]  R. Grose,et al.  Dysregulated FGF signalling in neoplastic disorders. , 2016, Seminars in cell & developmental biology.

[12]  Jian Xiao,et al.  Fibroblast growth factors, old kids on the new block. , 2016, Seminars in cell & developmental biology.

[13]  A. Russo,et al.  Nintedanib in NSCLC: evidence to date and place in therapy , 2016, Therapeutic advances in medical oncology.

[14]  M. Varella‐Garcia,et al.  Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. , 2016, Current molecular medicine.

[15]  Y. Assaraf,et al.  Lysosomes as mediators of drug resistance in cancer. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[16]  G. Knott,et al.  NanoSIMS analysis of an isotopically labelled organometallic ruthenium(II) drug to probe its distribution and state in vitro. , 2015, Chemical communications.

[17]  P. Lv,et al.  Simultaneous determination of nintedanib and its metabolite BIBF 1202 in different tissues of mice by UPLC-MS/MS and its application in drug tissue distribution study. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  Razelle Kurzrock,et al.  The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.

[19]  S. Sleijfer,et al.  Lysosomal Sequestration Determines Intracellular Imatinib Levels , 2015, Molecular Pharmacology.

[20]  F. André,et al.  Targeting FGFR Signaling in Cancer , 2015, Clinical Cancer Research.

[21]  L. Raez,et al.  Nintedanib in non-small cell lung cancer: from preclinical to approval , 2015, Therapeutic advances in respiratory disease.

[22]  H. Verheul,et al.  The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer , 2015, Journal of kidney cancer and VHL.

[23]  R. Kaiser,et al.  Nintedanib: from discovery to the clinic. , 2015, Journal of medicinal chemistry.

[24]  Y. Assaraf,et al.  Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance , 2014, Oncotarget.

[25]  Dan Fu,et al.  Imaging the Intracellular Distribution of Tyrosine Kinase Inhibitors in Living Cells with Quantitative Hyperspectral Stimulated Raman Scattering , 2014, Nature chemistry.

[26]  F. Hirsch,et al.  FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies , 2014, Clinical Cancer Research.

[27]  H. Nakagama,et al.  FGF Receptors: Cancer Biology and Therapeutics , 2014, Medicinal research reviews.

[28]  W. Berger,et al.  Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. , 2012, Cancer research.

[29]  Andrew P Thomas,et al.  AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. , 2012, Cancer research.

[30]  A. Ballabio,et al.  A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB , 2012, The EMBO journal.

[31]  W. Berger,et al.  Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy , 2011, Expert opinion on therapeutic targets.

[32]  Yvonne Will,et al.  A high content screening assay for identifying lysosomotropic compounds. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[33]  Kenneth W Dunn,et al.  A practical guide to evaluating colocalization in biological microscopy. , 2011, American journal of physiology. Cell physiology.

[34]  F. Ahmad,et al.  The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review , 2011, Expert opinion on therapeutic patents.

[35]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[36]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[37]  Johannes Kornhuber,et al.  Quantitative modeling of selective lysosomal targeting for drug design , 2008, European Biophysics Journal.

[38]  Sylvain V Costes,et al.  Automatic and quantitative measurement of protein-protein colocalization in live cells. , 2004, Biophysical journal.

[39]  A. Wiedlocha,et al.  Signaling, internalization, and intracellular activity of fibroblast growth factor. , 2004, Current topics in microbiology and immunology.

[40]  W. Langdon,et al.  Cbl: many adaptations to regulate protein tyrosine kinases , 2001, Nature Reviews Molecular Cell Biology.

[41]  Y. Moriyama,et al.  Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. , 1991, The Journal of biological chemistry.

[42]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[43]  P. Tulkens,et al.  Commentary. Lysosomotropic agents. , 1974, Biochemical pharmacology.